Glenn Wilkins - Thursday, December 29, 2016 Aptose Biosciences Inc. 11:41 AM EST - Aptose Biosciences Inc. : Provided an update on the development of APTO-253, its investigational compound for acute myeloid leukemia. Aptose Biosciences Inc. shares T.APS are trading down $0.15 at $1.78.